← Leaderboards
Bill Thelin
Parion Sciences, Inc.
$2,833,021
Attributed
$4,752,383
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2013–23$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,752,383 · 6
By mechanism
R44$3,882,806 · 3
R43$869,577 · 3
Top collaborators
- Christopher Eldridge Sims5 shared
- Jose Boyer1 shared
Others in their field
Top investigators on “Gastrointestinal”
- Walter John Curran · Thomas Jefferson University$113,335,296
- Norman Wolmark · Nsabp Foundation, Inc.$110,687,094
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$74,478,591
- Charles A Coltman · Southwest Oncology Group$58,629,817
- Richard L Schilsky · University Of Chicago$54,781,085
- Susan Abushakra · Alzheon, Inc.$47,690,244
Research focus
GastrointestinalPharmaceutical PreparationsColonPharmacologic SubstanceIn VitroGastrointestinal EpitheliumStem CellsCellsIntestinesMonolayerNovel TherapeuticsTechnologyInflammationTumor Cell LineCell Differentiation ProcessScreeningApicalBiological ModelsReproducibilitySmall IntestinesOrganoidsPhysiologyHuman Stem CellsCell Survival
Grant awards (7)
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$988,414
R44 · FY2023 · TR · contact PI
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$913,659
R44 · FY2023 · TR · contact PI
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation$992,302
R44 · FY2022 · TR · contact PI
A 2D Intestinal Crypt Platform for Compound Screens$988,431
R44 · FY2022 · DK · contact PI
A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing$293,991
R43 · FY2022 · DK · contact PI
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk$256,574
R43 · FY2022 · TR · contact PI
Novel Mucolytic Agents$319,012
R43 · FY2013 · HL · contact PI